2nd Edition of International Cancer & Immuno-Oncology Conference
March 19-21, 2026 | Singapore
Experimental Chemotherapy
Experimental chemotherapy represents an innovative frontier in cancer research, aiming to enhance treatment efficacy while minimizing adverse effects. This cutting-edge approach involves the exploration of novel drugs, combination therapies, and targeted delivery systems. Researchers are delving into personalized chemotherapy regimens tailored to individual genetic profiles, potentially maximizing therapeutic outcomes. Moreover, experimental chemotherapy encompasses the development of immunotherapy agents that harness the body's immune system to combat cancer cells selectively. By pushing the boundaries of traditional chemotherapy, scientists strive to overcome drug resistance, reduce toxicity, and improve overall patient survival rates. While still in the experimental stages, these advancements hold promise for revolutionizing cancer treatment paradigms, offering hope for more effective and tolerable therapies in the fight against cancer.
Rajvir Dahiya
University of California San Francisco, United States
Atif A Ahmed
University of Washington-Seattle Children’s Hospital, United States
Anyou Wang
DIFIBER LLC, United States
Paulo Cesar De Morais
Catholic University of Brasilia, Brazil
Allen Chen
Olympic Medical Center, United States
Shilpa S Dhar
UT MD Anderson Cancer Center, United States
Ritu Khanna
University of Manchester, United KingdomSubmit your abstract Today
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China